Summary: An international research team led by the Central Institute of Mental Health (CIMH) in Mannheim has reported the largest genome-wide association study (GWAS) of borderline personality disorder (BPD) to date. Analyzing genetic data from roughly 13,000 people with BPD and more than 1.1 million controls across 14 countries, the study identified 11 independent genomic risk regions (loci) and nine candidate genes. The results show that common genetic variants explain an estimated 17.3% of BPD liability and that polygenic risk scores explain about 4.6% of variance, confirming a highly polygenic architecture with substantial genetic overlap with other psychiatric and some physical conditions.
Key Facts
- Largest GWAS to date: Analysis included ~12,339 cases in the discovery sample and >1.04 million controls, plus a replication cohort.
- Risk loci and genes: 11 independent genomic loci and nine candidate genes were implicated in BPD susceptibility.
- Heritability and prediction: SNP-based heritability estimated at 17.3%; polygenic score predicted 4.6% of phenotypic variance on the liability scale.
- Transdiagnostic overlap: Strong positive genetic correlations with PTSD, major depression, ADHD, antisocial behavior, and suicidal/self-injurious behaviors; additional links to COPD and type 2 diabetes were observed.
- Open science for drug discovery: Summary statistics will be made available to accelerate functional follow-up and support therapeutic development.
Source: CIMH
Borderline personality disorder is a debilitating psychiatric condition marked by emotional instability, impulsivity, identity disturbance, and difficulties in relationships. It typically emerges in adolescence and is estimated to affect approximately 0.9%–1.9% of people in Western countries, with greater diagnosis rates in women. BPD frequently co-occurs with self-harm, suicidal ideation, and other psychiatric or somatic illnesses, yet the biological underpinnings have remained incompletely understood. This GWAS provides new, robust genomic evidence clarifying part of that biology.
11 risk regions and nine candidate genes
The international consortium screened millions of single-nucleotide polymorphisms (SNPs) across large, well-powered cohorts to detect common variant associations with BPD. The analysis identified 11 independent genomic loci associated with increased risk and nine genes that emerged from gene-based analyses as plausible contributors to disorder biology. While each locus exerts a small effect individually, together they reinforce a polygenic model where many common variants cumulatively shape vulnerability.
Genetic proportion and predictive power
SNP heritability was estimated at 17.3%, indicating that a meaningful fraction of BPD susceptibility is captured by common variants analyzed in GWAS. Derived polygenic scores (PGS) explained 4.6% of phenotypic variance on the liability scale in independent data. These metrics confirm that genetic information can contribute to risk stratification, though current predictive power is modest and not yet suitable for clinical diagnosis by itself.
As Dr. Stephanie Witt of CIMH emphasizes, the findings mark a major step toward understanding BPD’s genetic architecture and show that, like other psychiatric disorders, BPD is highly polygenic.
Broad overlap with other diseases
Comprehensive correlation and phenome-wide analyses demonstrated substantial genetic sharing between BPD and several psychiatric disorders—most strongly PTSD, major depressive disorder, ADHD, antisocial behavior, and measures of suicide and self-harm. Using BPD polygenic scores in biobank data further revealed associations with somatic conditions such as chronic obstructive pulmonary disease (COPD) and diabetes. These results support a transdiagnostic framework in which overlapping genetic pathways predispose individuals to multiple mental and physical health outcomes.
Lead authors note the parallels to early schizophrenia GWAS efforts, which initially discovered a few loci and later achieved exponential growth in gene discovery as sample sizes and ancestral diversity increased. The study team recommends expanding cohorts across diverse ancestries, improving phenotyping, and integrating multi-omics and environmental measures (for example, trauma exposure) to clarify mechanisms and guide targeted interventions.
Data sharing and research implications
To accelerate follow-up functional studies and drug discovery, the consortium is making full summary statistics available to the scientific community. Prior evidence indicates that therapeutics informed by human genetics are more likely to succeed in clinical trials, so these data could help prioritize targets and inform translational projects aimed at improving care for people with BPD.
Key Questions Answered:
A: It is the largest genetic study of BPD to date and provides the first robust, large-scale evidence that BPD has a polygenic basis, identifying specific loci and candidate genes that can be the focus of future biological and therapeutic research.
A: The study found strong genetic correlations between BPD and multiple psychiatric disorders as well as some medical conditions, indicating shared biological pathways that increase risk across diagnostic boundaries and supporting transdiagnostic approaches to care.
A: Early schizophrenia GWAS initially identified only a few loci but rapidly expanded as international collaborations increased sample sizes and diversity. Researchers expect BPD genetics to follow a similar growth curve as cohorts expand and analyses integrate environmental and multi-omic data.
Editorial Notes:
- Edited by a Neuroscience News editor.
- Journal article reviewed in full by editorial staff.
- Additional context and clarification added by editors to improve readability.
About this BPD and genetics research news
Author: Torsten Lauer
Source: CIMH
Contact: Torsten Lauer – CIMH
Image: The image is credited to Neuroscience News
Original Research: Open access. “Genome-wide association analyses of borderline personality disorder identify 11 loci and highlight shared risk with mental and somatic disorders” by Fabian Streit et al., published in Nature Genetics. DOI: 10.1038/s41588-026-02654-3.
Abstract (condensed): This GWAS meta-analysis of BPD combined a discovery sample of 12,339 cases and 1,041,717 controls with a replication cohort, all of European ancestry. The study identified 11 independent loci and nine risk genes, estimated SNP heritability at 17.3%, and derived polygenic scores explaining 4.6% of liability variance. BPD showed the strongest genetic correlations with PTSD, depression, ADHD, antisocial behavior, and suicidal/self-harm measures. Phenome-wide scans using BPD-PGS in large biobanks also linked genetic risk to somatic conditions such as COPD and diabetes. Overall, the results position BPD as a polygenic disorder with genetic risk shared across psychiatric and somatic health domains.